Key result
Generic statins linked to ~8% lower adverse outcomes vs brand-name statins, alongside higher adherence.
Cohort (n=90,111)
Answers are grounded in this paper and cite their sources.
BACKGROUND: Statins are effective in preventing cardiovascular events, but patients do not fully adhere to them. OBJECTIVE: To determine whether patients are more adherent to generic statins versus brand-name statins (lovastatin, pravastatin, or simvastatin) and whether greater adherence improves health outcomes. DESIGN: Observational, propensity score-matched, new-user cohort study. SETTING: Linked electronic data from medical and pharmacy claims. PARTICIPANTS: Medicare beneficiaries aged 65 years or older with prescription drug coverage between 2006 and 2008. INTERVENTION: Initiation of a generic or brand-name statin. MEASUREMENTS: Adherence to statin therapy (measured as the proportion of days covered [PDC] up to 1 year) and a composite outcome comprising hospitalization for an acute coronary syndrome or stroke and all-cause mortality. Hazard ratios (HRs) and absolute rate differences were estimated. RESULTS: A total of 90,111 patients who initiated a statin during the study was identified; 83,731 (93%) initiated a generic drug, and 6380 (7%) initiated a brand-name drug. The mean age of patients was 75.6 years, and most (61%) were female. The average PDC was 77% for patients in the generic group and 71% for those in the brand-name group (P<0.001). An 8% reduction in the rate of the clinical outcome was observed among patients in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]). The absolute difference was -1.53 events per 100 person-years (CI, -2.69 to -0.19 events per 100 person-years). LIMITATION: Results may not be generalizable to other populations with different incomes or drug benefit structures. CONCLUSION: Compared with those initiating brand-name statins, patients initiating generic statins were more likely to adhere and had a lower rate of a composite clinical outcome. PRIMARY FUNDING SOURCE: Teva Pharmaceuticals.
No takes yet. Share an insight, caveat, or question.
Gagne et al. (2014) conducted a cohort in Cardiovascular event prevention (statin therapy initiation) (n=90,111). Generic statin (lovastatin, pravastatin, or simvastatin) vs. Brand-name statin (lovastatin, pravastatin, or simvastatin) was evaluated on Composite of hospitalization for an acute coronary syndrome or stroke and all-cause mortality (and statin adherence measured by proportion of days covered up to 1 year) (HR 0.92, 95% CI 0.86-0.99, p=<0.001). Initiating generic statins vs brand-name statins increased adherence and reduced ACS, stroke, or all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: